Announced on September 4, 2024, this acquisition positions uMotif to enhance its existing capabilities by integrating ClinOne’s enterprise consent management, site productivity tools, and trial awareness solutions into its modern electronic Clinical Outcome Assessments (eCOA) and electronic Patient-Reported Outcomes (ePRO) platform.
This strategic move strengthens uMotif’s commitment to improving both the patient and site experience in clinical trials and real-world studies, a goal that has been central to the company’s rapid growth. According to uMotif, their eCOA/ePRO platform is already one of the most advanced on the market, driving unprecedented levels of patient compliance by guiding participants through every step of the trial process. The platform is known for putting patients’ needs first, which has helped sponsors and contract research organizations (CROs) gather the large amounts of data necessary to maximize trial success.
ClinOne’s integration brings added capabilities to uMotif’s platform, including improved consent management, enhanced site productivity, and a better patient and caregiver experience, all of which are supported by comprehensive data insight tools and standards-based interoperability. The acquisition builds on a successful two-year partnership between the two companies, during which they collaborated to provide sponsors and CROs with a single, integrated solution that addresses both the site and patient journey.
“The acquisition of ClinOne is a logical next step for uMotif after years of collaboration,” said Steve Rosenburg, CEO at uMotif. “It allows us to bring our combined expertise to more sponsors and CROs, delivering the most user-friendly, patient-first solutions available today.”
ClinOne, headquartered in Denver, Colorado, is known for its technology that connects, informs, and empowers clinical trial sites through a single integrated platform. In particular, ClinOne’s best-in-class eConsent management system has been widely adopted by sponsors looking to increase patient engagement and compliance. The platform’s solutions also help streamline site operations, enhance trial awareness among healthcare providers, and offer innovative features like Uber Health patient transportation.
With these capabilities now integrated into uMotif’s offerings, the company aims to provide sponsors with an all-in-one solution that not only supports patients through eCOA/ePRO but also enhances the productivity of clinical sites.
The acquisition comes at a time of hypergrowth for uMotif, further underscored by the recent appointment of Florence (Flo) Mowlem, as Chief Scientific Officer (CSO). Announced on
September 10, 2024, the addition of Mowlem to the senior leadership team brings significant expertise in the digital capture of clinical outcomes assessments (COAs), including patient-reported outcomes (PROs) and clinician-reported outcomes (ClinROs). Her experience spans the intersection of science and technology, having worked with leading clinical technology companies such as Medable and Signant Health.
Mowlem, renowned for her work in guiding sponsors on the use of electronic COA tools, will provide scientific leadership across all functional areas at uMotif. Her role is designed to ensure that scientific rigor is embedded in the company’s processes, helping sponsors meet the ever-evolving scientific and regulatory needs of clinical research programs.
“I’m thrilled to join uMotif at such an exciting time of growth and innovation,” said Mowlem. “The integration of ClinOne’s platform with uMotif’s existing eCOA/ePRO tools offers sponsors a unique solution that addresses both scientific and operational challenges in clinical trials. I look forward to contributing to this next phase of growth and continuing to support sponsors in their efforts to capture meaningful data that drives clinical research forward.”
The combination of ClinOne’s capabilities with uMotif’s patient-first platform is expected to be a game-changer for the clinical research industry, providing a modern, integrated solution for clinical trials and real-world studies. With Mowlem’s scientific leadership and the enhanced tools now available, uMotif is well-positioned to set new benchmarks in patient compliance, site productivity, and trial success.
Both companies are committed to using their combined expertise to help sponsors and CROs meet the evolving demands of clinical trials. As the clinical research landscape continues to prioritize patient-centric approaches and technology-driven efficiencies, uMotif’s latest acquisition is seen as a critical step toward shaping the future of clinical research technology.
